2. Cancer
  3. Cancer Targeted Therapy

Cancer Targeted Therapy

Cancer targeted therapy is the foundation of precision medicine; it uses drugs or other substances to target specific genes and proteins that control cancer cells’ growth, division and spreading. Compared to traditional chemotherapy drugs, targeted-drugs can specifically act on cancer cells with high efficacy without damaging normal cells. Drugs used in cancer targeted therapy mainly includes small molecules and macromolecules (e.g., monoclonal antibodies), which can target cancer cells and constituents in the tumor microenvironment to activate the immune system. Anti-angiogenesis drugs, such as those targeting vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), transforming growth factor (TGF)-α, TGF-β, Tumor necrosis factor (TNF)-α, and platelet-derived endothelial growth factor (PDGFR) inhibit the proliferation and metastasis of cancer cells. In recent years, the proportion of antibody drugs in cancer treatment has gradually become prominent. Antibody-drug conjugates (ADCs) are a new type of targeted drugs that are composed of monoclonal antibody, cytotoxic drug and linker. ADCs can deliver drugs to tumor cells and minimize the toxicity to normal tissues. Proteolysis-targeting chimera (PROTAC) is a useful technology for targeted protein degradation. PROTAC exploits the ubiquitin-proteasome system and forms a ternary complex with a hijacked E3 ubiquitin ligase and target protein, leading to polyubiquitination and degradation of the target protein.

Targeted therapy is a useful strategy in treatment of cancer either alone or in combination with standard chemotherapy. At present, targeted therapy has proved significant clinical success in the treatment of many types of cancer, including breast cancer, colorectal cancer, leukemia, ovarian cancer and lung cancer.

Cancer Targeted Therapy Related Products (35100):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-134290
    8-Chloro-ATP 185341-71-3
    8-Chloro-ATP, an ATP (HY-B2176) analog, is a topoisomerase II (Topo II) inhibitor. 8-Chloro-ATP inhibits DNA synthesis and induces DNA double-stranded breaks (DSBs). 8-Chloro-ATP inhibits Topo II-catalyzed ATP hydrolysis.
    8-Chloro-ATP
  • HY-49556
    (S)-Benzyl 2-cyclopropyl-2-hydroxyacetate 2414393-48-7 98.69%
    (S)-Benzyl 2-cyclopropyl-2-hydroxyacetate is an intermediate reactant in the synthesis of Camptothecin (HY-16560). Camptothecin is an inhibitor of the DNA topoisomerase Topo I, withIC50=679 nM.
    (S)-Benzyl 2-cyclopropyl-2-hydroxyacetate
  • HY-125151
    BP-1-108 1334492-85-1
    BP-1-108 is a selective inhibitor of STAT5 (Ki=8.3 μM) with anticancer activity. BP-1-108 induces apoptosis of leukemia cells by inhibiting the phosphorylation of STAT5. BP-1-108 can be used in the study of acute myeloid leukemia and prostate cancer.
    BP-1-108
  • HY-139227
    Thalidomide 4'-oxyacetamide-C1-PEG3-C3-amine hydrochloride 2564466-93-7
    Thalidomide 4'-oxyacetamide-C1-PEG3-C3-amine hydrochloride is a functionalized cereblon ligand for PROTAC research and development with terminal amine ready for conjugation to a target protein ligand.
    Thalidomide 4'-oxyacetamide-C1-PEG3-C3-amine hydrochloride
  • HY-168768
    FerroLOXIN-1 2773428-48-9
    FerroLOXIN-1 is a potent inhibitor of 15LOX-2 that selectively blocked production of pro-ferroptotic HOO-ETE-PE and protected against RSL3-induced ferroptosis. FerroLOXIN-1 closely interacted therein with 15LOX-2 only, and in particular with Y154, N155, W158.
    FerroLOXIN-1
  • HY-10182AR
    Laduviglusib monohydrochloride (Standard) 1797989-42-4
    Laduviglusib (monohydrochloride) (Standard) is the analytical standard of Laduviglusib (monohydrochloride). This product is intended for research and analytical applications. Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib monohydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib monohydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib monohydrochloride induces autophagy.
    Laduviglusib monohydrochloride (Standard)
  • HY-161961
    Thalidomide-NH-C10-Boc 2428400-25-1
    Thalidomide-NH-C10-Boc (compound S20) is a conjugate of the E3 ubiquitinase ligand Thalidomide and PROTAC Linker, which can recruit Cereblon ubiquitinase. Thalidomide-NH-C10-Boc can couple the target protein ligand through the PTOTAC Linker to synthesize PROTAC molecules with degradation effects. For example, Thalidomide-NH-C10-Boc can couple with the ligand EP300/CBP ligand 2 (HY-161960) to produce the PROTAC molecule dCE-2 (HY-161958).
    Thalidomide-NH-C10-Boc
  • HY-N0534R
    Vitexin-2"-O-rhamnoside (Standard) 64820-99-1
    Vitexin-2"-O-rhamnoside (Standard) is the analytical standard of Vitexin-2"-O-rhamnoside (HY-N0534). This product is intended for research and analytical applications. Vitexin-2"-O-rhamnoside is an orally active flavonoid glycoside. Vitexin-2"-O-rhamnoside inhibits Apoptosis, increases the phosphorylation levels of PI3K/Akt, inhibits caspase-3, SOD activity, and promotes cytokine (IL-2, IL-6, and IL-12) secretion. Vitexin-2"-O-rhamnoside strongly inhibits DNA synthesis in MCF-7 cells with an IC50 of 17.5 μM. Vitexin-2"-O-rhamnoside enhances immune function and improves the absorption of active compounds. Vitexin-2"-O-rhamnoside has antioxidant activity. Vitexin-2"-O-rhamnoside is used in the study of cardiovascular disease and immune-related diseases.
    Vitexin-2
  • HY-130881
    HS-PEG6-CH2CH2-Boc 1818294-40-4
    HS-PEG6-CH2CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
    HS-PEG6-CH2CH2-Boc
  • HY-123232
    KU-0058684 623578-11-0
    KU-0058684 is a potent PARP inhibitor, with an IC50 of 3.2 nM for PARP-1. KU-0058684 significantly reduces DNA double strand break (DSB) repair.
    KU-0058684
  • HY-12408
    6H05 1469338-01-9
    6H05 is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).
    6H05
  • HY-W800652
    (S,R,S)-AHPC-PEG4-tosyl 2839806-91-4
    (S, R, S)-AHPC-PEG4-tosyl is a PROTAC linker that incorporatess an E3 ligase ligand with a PEG4 linker to empower PROTAC drug research & discovery. PEG4 spacer increases the compound's hydrophility. Tosyl group is reactive with amine or other nucleophiles.
    (S,R,S)-AHPC-PEG4-tosyl
  • HY-B0553R
    Methazolamide (Standard) 554-57-4
    Methazolamide (Standard) is the analytical standard of Methazolamide. This product is intended for research and analytical applications. Methazolamide (L584601) is a BBB-penetrable and orally active carbonic anhydrase inhibitor, with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide can reduce intraocular pressure and has a neuroprotective effect, being able to inhibit neuronal apoptosis. Methazolamide can be used in the research of ophthalmic diseases such as glaucoma and cerebrovascular diseases such as subarachnoid hemorrhage.
    Methazolamide (Standard)
  • HY-B1455R
    Clindamycin (Standard) 18323-44-9
    Clindamycin (Standard) is the analytical standard of Clindamycin. This product is intended for research and analytical applications. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria.
    Clindamycin (Standard)
  • HY-117591
    L 684248 156728-18-6
    L-684248 is an inhibitor of human leukocyte elastase (HLE). L-684248 exerts its inhibitory effect on HLE by forming a covalent bond with the active site of the enzyme, showing potential value for applications in anti-inflammatory and anti-tumor research.
    L 684248
  • HY-W751574
    Elagolix-d6 sodium
    Elagolix-d6 (sodium) (NBI-56418-d6 (sodium)) is deuterium labeled Elagolix sodium. Elagolix sodium is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (KD = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .
    Elagolix-d<sub>6</sub> sodium
  • HY-16126R
    Carboxyamidotriazole (Standard) 99519-84-3
    Carboxyamidotriazole (Standard) is the analytical standard of Carboxyamidotriazole. This product is intended for research and analytical applications. Carboxyamidotriazole (L-651582) is a cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways. Carboxyamidotriazole shows anti-tumor, anti-inflammatory and antiangiogenic effects.
    Carboxyamidotriazole (Standard)
  • HY-48625
    L2H2-6OTD intermediate-2 890403-75-5 99.72%
    L2H2-6OTD intermediate-2 is an intermediate of telomerase inhibitor, which can be used in the synthesis of ADC.
    L2H2-6OTD intermediate-2
  • HY-163647
    Lenalidomide-COCH-PEG2-azido 2380273-88-9
    Lenalidomide-COCH-PEG2-azido is a synthesized E3 ligase ligand-linker conjugate that incorporates the Lenalidomide (HY-A0003) based cereblon ligand and a linker. Lenalidomide-COCH-PEG2-azido can be used in the synthesis of PROTAC AKR1C3 degrader-1 (HY-163609).
    Lenalidomide-COCH-PEG2-azido
  • HY-169368
    Thalidomide-O-Triazole-C4-amino 2412988-59-9
    Thalidomide-O-Triazole-C4-amino is an E3 ligase ligand-linker conjugate. Thalidomide-O-Triazole-C4-amino can be used to synthesize aTAG 4531 (HY-163168).
    Thalidomide-O-Triazole-C4-amino